All In Biotech

Drug Trial Radar · NCT01327053

A Phase II Study of Efficacy and Safety in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Phase II, Randomized Double-blind Study of Efficacy and Safety of Two Dose Levels of LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma

Last checked: Nov 19, 2026Latest source record: Aug 28, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 230 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

230

Actual

Start

Jun 29, 2011

Primary completion

Jun 28, 2013

Study completion Jun 29, 2018

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Apr 1, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study assessed the efficacy and safety of oral treatment with two dose levels of LDE225 in patients with locally advanced or metastatic BCC.

Conditions

  • Basal Cell Carcinoma

Interventions

  • LDE225Drug

    LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (for Metastatic Basal Cell Carcinoma (mBCC)) Per Primary Efficacy Analysis Set (pEAS)Time frame: 6 months
  2. Objective Response Rate (ORR) Based on Central Review According to mRECIST (for Locally Advanced Basal Cell Carcinoma (laBCC)) and RECIST 1.1 (Metastatic Basal Cell Carcinoma (mBCC)) Per Full Analysis Set (FAS)Time frame: 6 months

Locations

62 sites in 12 countries. Site status is shown where the registry gives one.

  • Highlands Oncology Group

    Fayetteville, Arkansas

  • University of California at Los Angeles UCLA 3

    Los Angeles, California

  • Stanford University Medical Center Stanford Univ 2

    Stanford, California

  • University of Colorado School of Medicine UC

    Aurora, Colorado

  • Washington Hospital Center Wash Hospital

    Washington D.C., District of Columbia

  • H Lee Moffitt Cancer Center and Research Institute Cutaneous Onc Dept

    Tampa, Florida

  • NorthwesternUniv.Med.School/Robert H. Lurie Comp.Cancer Ctr Study coordinator

    Chicago, Illinois

  • Dana Farber Cancer Institute DFCI - MA

    Boston, Massachusetts

  • Henry Ford Hospital Henry Ford

    Detroit, Michigan

  • Washington University School Of Medicine-Siteman Cancer Ctr Siteman

    St Louis, Missouri

  • Comprehensive Cancer Centers of Nevada CCC of Nevada- Southwest (2)

    Las Vegas, Nevada

  • Hackensack University Medical Center Hackensack (SC)

    Hackensack, New Jersey

  • New York University Medical Center SC-2

    New York, New York

  • Penn State University / Milton S. Hershey Medical Center Hershey Medical

    Hershey, Pennsylvania

  • University of Pittsburgh Medical Center UPMC

    Pittsburgh, Pennsylvania

  • Baylor Health Care System/Sammons Cancer Center Baylor Texas Oncology

    Dallas, Texas

  • Texas Oncology Tex Onc 3

    Dallas, Texas

  • Texas Oncology Texas Onc - Amarillo

    Dallas, Texas

  • University of Texas MD Anderson Cancer Center MD Anderson

    Houston, Texas

  • Texas Oncology Cancer Care & Research Center

    Waco, Texas

  • Texoma Cancer Center Texoma Cancer Center

    Wichita Falls, Texas

  • University of Utah / Huntsman Cancer Institute Huntsman/Univ UT

    Salt Lake City, Utah

  • Novartis Investigative Site

    St Leonards, New South Wales, Australia

  • Novartis Investigative Site

    Geelong, Victoria, Australia

  • Novartis Investigative Site

    Brussels, Belgium

  • Novartis Investigative Site

    Wilrijk, Belgium

  • Novartis Investigative Site

    Waterloo, Ontario, Canada

  • Novartis Investigative Site

    Sainte-Foy, Quebec, Canada

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Marseille, France

  • Novartis Investigative Site

    Pierre-Bénite, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Villejuif, France

  • Novartis Investigative Site

    Berlin, Germany

  • Novartis Investigative Site

    Essen, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, Germany

  • Novartis Investigative Site

    Gera, Germany

  • Novartis Investigative Site

    Hanover, Germany

  • Novartis Investigative Site

    Kiel, Germany

  • Novartis Investigative Site

    Mainz, Germany

Showing 40 of 62 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.